Sobi publishes Annual Report 2013

Swedish Orphan Biovitrum AB (publ) (Sobi) today published its Annual Report for 2013, themed "Pioneer in Rare Diseases", on the company's website, www.sobi.com. 

The Annual Report summarises 2013, which was an eventful year for Sobi with several key milestones, and encompasses the company's approach to keeping the patient journey - from diagnosis and treatment, to on-going disease management and long-term outcomes - at the centre of how it prioritises its capabilities and investments. By creating and maintaining a dialogue with key stakeholders (patients organisations, physicians, governments and payers), Sobi seeks to ensure that treatments are delivered in a sustainable way. Sobi refers to this approach as Patient and Customer Centric Commercialisation.

Sobi's Annual Report also includes interviews with key industry stakeholders as well as patients, giving their perspective on the development of the pharmaceutical industry and how it is to live with a rare disease, respectively.

---

About Sobi
Sobi is an international specialty healthcare company dedicated to rare diseases. Our mission is to develop and deliver innovative therapies and services to improve the lives of patients. The product portfolio is primarily focused on Inflammation and Genetic diseases, with three late stage biological development projects within Haemophilia and Neonatology. We also market a portfolio of specialty and rare disease products for partner companies. Sobi is a pioneer in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing. In 2013, Sobi had total revenues of SEK 2.2 billion (€253 M) and about 550 employees. The share (STO: SOBI) is listed on Nasdaq OMX Stockholm. More information is available at www.sobi.com.

For more information please contact

Media relationsInvestor relationsOskar BossonJörgen WinrothHead of Communications                Vice President, Head of Investor RelationsT: +46 70 410 71 80 T: +1 347-224-0819, +46 8 697 2135oskar.bosson@sobi.com   jorgen.winroth@sobi.comPdf version of press release


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Swedish Orphan Biovitrum AB (publ) via Globenewswire
HUG#1777618